CalciMedica
LA JOLLA, CA · Biotechnology, Healthcare · 16 employees
CalciMedica is a privately held, clinical stage biotechnology company with a platform focused on CRAC channel drug discovery and development for the treatment of acute and severe inflammatory diseases. The Company was founded in 2007 by Ken Stauderman, CalciMedica’s Chief Scientific Officer, and colleagues at Torrey Pines Therapeutics in San Diego and Harvard’s Center for Blood Research in Cambrid
Funding history
- Funding Round — $32.5M — Mar 2025
- Funding Round — $9.1M — Apr 2023
- Funding Round — $10.3M — Apr 2023
- Funding Round — $17.2M — May 2020
- Funding Round — $55.0M — Aug 2019
Recent signals
- Jan 28, 2026: SEC 8-K (7.01): On January 28, 2026, CalciMedica, Inc. announced the discontinuation of its Phase 2 KOURAGE clinical trial evaluating Auxora TM in patients suffering from Stage 2 or Stage 3 acute kidney injury (AKI) associated with acute hypoxemic respiratory failure (AHRF). This decision was made following a recommendation from the trial's Independent Data Monitoring Committee (IDMC). The trial discontinuation may have significant implications for the company's strategy and future development plans regarding Auxora TM, particularly in the context of treating AKI and AHRF patients. A copy of the press release detailing this decision is attached as Exhibit 99.1.
- Mar 05, 2025: Raised $32.5M
- Nov 07, 2024: CalciMedica Appoints Stephen Bardin as Chief Financial Officer
- Apr 04, 2023: Raised $9.1M
- Apr 04, 2023: Raised $10.3M
- May 27, 2020: Raised $17.2M
- Aug 15, 2019: Raised $55.0M
- Jun 13, 2018: Raised $75.4M
See plans & pricing → Track CalciMedica’s funding, hiring, and signals — with verified contacts — on Fundz.